Monashee Investment Management’s BridgeBio Pharma BBIO Stock Holding History

Monashee Investment Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-67,139	Closed	-$4.99M	–	26
2026 Q1	$4.99M	Sell	67,139 -32,861	-33%	-$2.38M	2.71%	11
2025 Q4	$7.65M	Sell	100,000 -100,000	-50%	-$6.56M	4.31%	9
2025 Q3	$10.4M	Sell	200,000 -55,000	-22%	-$2.68M	5.18%	1
2025 Q2	$11M	Buy	255,000 +80,000	+46%	+$2.91M	3.99%	6
2025 Q1	$6.05M	Buy	+175,000	New	+$5.9M	0.72%	20
2024 Q2	–	Sell	-60,000	Closed	-$1.86M	–	83
2024 Q1	$1.86M	Buy	+60,000	New	+$2.04M	0.22%	73
2019 Q3	–	Sell	-50,000	Closed	-$1.35M	–	123
2019 Q2	$1.35M	Buy	+50,000	New	+$1.36M	0.35%	76

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Monashee Investment Management's BBIO Position: Q2 2026 in Review

Monashee Investment Management sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 67,139 shares — an estimated $4.99M sold.

Monashee Investment Management first reported a position in BBIO in Q2 2019 and held it in 7 quarters. The position peaked at $11M in Q2 2025. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Monashee Investment Management reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
Monashee Investment Management sold 67,139 BridgeBio Pharma shares in Q2 2026, an estimated $4.99M.
Monashee Investment Management first reported a position in BridgeBio Pharma in Q2 2019 and held it in 7 quarters.
Monashee Investment Management's BridgeBio Pharma position peaked at $11M in Q2 2025.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Monashee Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.